Literature DB >> 18694191

An automated communication system in a Contact Registry for persons with rare diseases: tools for retaining potential clinical research participants.

Rachel L Richesson1, Ken Young, Jennifer Lloyd, Tim Adams, Heather Guillette, Jamie Malloy, Jeffrey P Krischer.   

Abstract

Strategies to enhance recruitment are useful in clinical research network settings. Our network data center maintains a Contact Registry of patients who express a willingness to be contacted to enroll in clinical studies. An automated system generates periodic and customized communications to notify registrants of potential studies and network events. The majority of these communications are sent by email, although the system also supports postal communications. A database tracks the sending of all communications and facilitates reports of registry activity.

Entities:  

Mesh:

Year:  2007        PMID: 18694191

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  2 in total

Review 1.  Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium.

Authors:  Jennifer Seminara; Mendel Tuchman; Lauren Krivitzky; Jeffrey Krischer; Hye-Seung Lee; Cynthia Lemons; Matthias Baumgartner; Stephen Cederbaum; George A Diaz; Annette Feigenbaum; Renata C Gallagher; Cary O Harding; Douglas S Kerr; Brendan Lanpher; Brendan Lee; Uta Lichter-Konecki; Shawn E McCandless; J Lawrence Merritt; Mary Lou Oster-Granite; Margretta R Seashore; Tamar Stricker; Marshall Summar; Susan Waisbren; Marc Yudkoff; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2010-02-10       Impact factor: 4.797

2.  Assessing disease experience across the life span for individuals with osteogenesis imperfecta: challenges and opportunities for patient-reported outcomes (PROs) measurement: a pilot study.

Authors:  Laura L Tosi; Marianne K Floor; Christina M Dollar; Austin P Gillies; Tracy S Hart; David D Cuthbertson; V Reid Sutton; Jeffrey P Krischer
Journal:  Orphanet J Rare Dis       Date:  2019-01-29       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.